Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec ...

TEPEZZA, as the first FDA-approved treatment for thyroid eye disease, marks a major breakthrough in managing TED, addressing a critical medical gap for patients who have long had few treatment ...

This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length mult ...

BTD designation follows the initial receipt of BTD and Fast Track designation for petosemtamab for the treatment of patients with r/m HNSCC whose disease has progressed following treatment with ...

This important study explores the conserved role of IgM in both systemic and mucosal antiviral immunity in teleosts, challenging established views on the differential roles of IgT and IgM. The ...

We demonstrate here that administration of a CD154-specific monoclonal antibody (hu5C8 ... cross-reactive human IgG isotype-specific antibodies. IgG1 antibodies make up at least some component ...

Rituximab, a monoclonal antibody directed against the CD20 molecule found on pre-B cells and mature B cells (but not on plasma cells), was introduced in the late 1990s for the treatment of non ...

A thyroglobulin antibody (TgAb) test looks for certain antibodies that attack the thyroid. The presence of TbAb in high levels may indicate that someone has an autoimmune condition. To conduct a ...

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a condition of the nervous system that can be managed with lifestyle modifications or medications, depending on your individual needs.

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Anti-malarial monoclonal antibodies (mAbs) are another promising new tool that have been shown to be safe and efficacious against infection with Plasmodium falciparum, which is the deadliest ...